MAINtenance Afinitor (MAIN-A): A randomized trial comparing maintenance aromatase inhibitors (AIs) + everolimus (Afinitor) vs. AIs in patients withHR+ metastatic breast cancer with disease control after first line chemotherapy
Phase of Trial: Phase III
Latest Information Update: 28 Sep 2016
At a glance
- Drugs Everolimus (Primary) ; Anastrozole; Exemestane; Letrozole
- Indications Breast cancer
- Focus Therapeutic Use
- Acronyms MAIN-A
- 16 Sep 2016 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
- 16 Sep 2016 Planned primary completion date changed from 1 Feb 2017 to 1 Feb 2018.
- 06 Aug 2014 New trial record